Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Chief: Good Things Come To Those Who Wait

Executive Summary

In the company’s third-quarter conference call, Novartis CEO Joe Jimenez admitted that generic competition to its blockbuster Gleevec will continue to drag on the company in 2017. However, he touted a pipeline of 12 potential blockbusters and restructuring efforts over the past three years as evidence that the company will be positioned for growth from 2018.

Advertisement

Related Content

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
4Q Pharma Results Preview: J&J, Novartis, Bristol, Celgene, Biogen
Novartis Hopes Encore Can Lead To Eye-Watering Presbyopia Success
Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Multiple Sclerosis: Close To Being Conquered
Stockwatch: An Earnings Season Renaissance Fades
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel